CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-15 | Norwalk Leslie V Director | Option exercise 10b5-1 | +8,276 | $92.35 | $764K | 10,705 |
| 2025-12-15 | Norwalk Leslie V Director | Option exercise 10b5-1 | +1,724 | $84.95 | $146K | 12,429 |
| 2025-12-15 | Norwalk Leslie V Director | Sale 10b5-1 | −5,000 | $152.23 | $761K | 7,429 |
| 2025-12-15 | Norwalk Leslie V Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −8,276 | 557 | ||
| 2025-12-15 | Norwalk Leslie V Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −1,724 | 0 | ||
| 2025-12-08 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 | +4,376 | $43.24 | $189K | 47,781 |
| 2025-12-08 | Lippoldt Darin Chief Legal Officer | Sale 10b5-1 | −4,376 | $159.65 | $699K | 43,405 |
| 2025-12-08 | Lippoldt Darin Chief Legal Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −4,376 | 0 | ||
| 2025-12-03 | LYONS GARY A Director | Option exercise 10b5-1 | +15,000 | $47.89 | $718K | 135,482 |
| 2025-12-03 | LYONS GARY A Director | Sale 10b5-1 | −15,000 | $152.61 | $2.3M | 120,482 |
| 2025-12-03 | LYONS GARY A Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −15,000 | 0 | ||
| 2025-11-29 | Onyia Jude Chief Scientific Officer | Option exercise | +4,426 | 18,129 | ||
| 2025-11-29 | Onyia Jude Chief Scientific Officer | Shares withheld for taxes | −2,248 | $152.16 | $342K | 15,881 |
| 2025-11-29 | Onyia Jude Chief Scientific Officer | Option exercise · Restricted Stock Unit | −4,426 | 0 | ||
| 2025-11-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise | +12,830 | $35.99 | $462K | 57,723 |
| 2025-11-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Incentive Stock Option | −12,830 | 0 | ||
| 2025-11-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise 10b5-1 | +5,970 | $35.99 | $215K | 50,863 |
| 2025-11-28 | BENEVICH ERIC Chief Commercial Officer | Sale 10b5-1 | −5,970 | $151.74 | $906K | 44,893 |
| 2025-11-28 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Incentive Stock Option 10b5-1 | −5,970 | 6,860 | ||
| 2025-11-25 | MORROW GEORGE J Director | Option exercise 10b5-1 | +15,000 | $47.89 | $718K | 22,068 |
Page 16 of 49 · 963 trades